id: NEW:treatment_adverse_events_hemodialysis_patients_to_NEW:hcv_treatment_discontinuation
name: Treatment Adverse Events in Hemodialysis Patients â†’ HCV Treatment Discontinuation
from_node:
  node_id: NEW:treatment_adverse_events_hemodialysis_patients
  node_name: Treatment Adverse Events in Hemodialysis Patients
to_node:
  node_id: NEW:hcv_treatment_discontinuation
  node_name: HCV Treatment Discontinuation
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Hemodialysis patients receiving interferon-based HCV treatment experience
  high rates of adverse events due to altered drug pharmacokinetics and pre-existing
  comorbidities'
- 'Step 2: Flu-like syndrome occurs in approximately 41% of patients, causing significant
  discomfort and reduced quality of life'
- 'Step 3: Severe adverse events accumulate across multiple organ systems including
  hematological (cytopenia/anemia), thyroid dysfunction, gastrointestinal problems,
  cardiovascular complications, CNS effects, and infectious complications'
- 'Step 4: The cumulative burden of adverse events, particularly severe ones, leads
  to treatment discontinuation in approximately 11% of patients'
evidence:
  quality_rating: A
  n_studies: 38
  primary_citation: 'T Casanovas Taltavull et al. 2009. Results of hepatitis C virus
    treatment in patients on hemodialysis: data from published meta-analyses in 2008.
    Transplantation proceedings.'
  supporting_citations: []
description: 'Treatment adverse events in hemodialysis patients receiving interferon-based
  HCV therapy lead to treatment discontinuation in approximately 11% of patients.
  Adverse events occur in less than 50% of documented cases but include severe multi-system
  complications: flu-like syndrome (41%), anemia requiring intervention, thyroid dysfunction,
  cytopenia, gastrointestinal symptoms, cardiovascular problems, CNS effects, and
  infectious complications. The accumulated severity of these events necessitates
  treatment withdrawal.'
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 11.0
    type: percentage
    ci_lower: null
    ci_upper: null
  p_value: null
  sample_size: 1104
moderators:
- name: Flu-like syndrome severity
  direction: strengthens
  strength: strong
  description: Flu-like syndrome occurred in 41% of patients and was a primary driver
    of treatment withdrawal
- name: Anemia management
  direction: weakens
  strength: moderate
  description: Use of erythropoietin, IV iron, or transfusions may mitigate anemia-related
    discontinuation, though inconsistently reported
- name: Prior transplant history
  direction: strengthens
  strength: moderate
  description: Immunological adverse events including prior graft rejection increase
    discontinuation risk
